Figure 2 shows the cardiovascular considerations when selecting a TKI agent (18). Given the absence of biomarkers that predict the cardiovascular risk associated with BCR::ABL1 TKI therapy, traditional risk scores derived from the general population are usually used in CML patients as well. However, such scores may underestimate the risk (27). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.